Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore, Singapore.
PLoS One. 2011;6(6):e20932. doi: 10.1371/journal.pone.0020932. Epub 2011 Jun 9.
Phosphoinositide 3-kinase (PI3K)/Akt pathway is linked to the development of asthma. Anti-malarial drug artesunate is a semi-synthetic derivative of artemisinin, the principal active component of a medicinal plant Artemisia annua, and has been shown to inhibit PI3K/Akt activity. We hypothesized that artesunate may attenuate allergic asthma via inhibition of the PI3K/Akt signaling pathway.
METHODOLOGY/PRINCIPAL FINDINGS: Female BALB/c mice sensitized and challenged with ovalbumin (OVA) developed airway inflammation. Bronchoalveolar lavage fluid was assessed for total and differential cell counts, and cytokine and chemokine levels. Lung tissues were examined for cell infiltration and mucus hypersecretion, and the expression of inflammatory biomarkers. Airway hyperresponsiveness was monitored by direct airway resistance analysis. Artesunate dose-dependently inhibited OVA-induced increases in total and eosinophil counts, IL-4, IL-5, IL-13 and eotaxin levels in bronchoalveolar lavage fluid. It attenuated OVA-induced lung tissue eosinophilia and airway mucus production, mRNA expression of E-selectin, IL-17, IL-33 and Muc5ac in lung tissues, and airway hyperresponsiveness to methacholine. In normal human bronchial epithelial cells, artesunate blocked epidermal growth factor-induced phosphorylation of Akt and its downstream substrates tuberin, p70S6 kinase and 4E-binding protein 1, and transactivation of NF-κB. Similarly, artesunate blocked the phosphorylation of Akt and its downstream substrates in lung tissues from OVA-challenged mice. Anti-inflammatory effect of artesunate was further confirmed in a house dust mite mouse asthma model.
CONCLUSION/SIGNIFICANCE: Artesunate ameliorates experimental allergic airway inflammation probably via negative regulation of PI3K/Akt pathway and the downstream NF-κB activity. These findings provide a novel therapeutic value for artesunate in the treatment of allergic asthma.
磷酸肌醇 3-激酶(PI3K)/Akt 通路与哮喘的发生有关。抗疟药青蒿琥酯是青蒿素的半合成衍生物,青蒿素是药用植物黄花蒿的主要活性成分,已被证明能抑制 PI3K/Akt 活性。我们假设青蒿琥酯可能通过抑制 PI3K/Akt 信号通路来减轻过敏性哮喘。
方法/主要发现:卵清蛋白(OVA)致敏和激发的雌性 BALB/c 小鼠发生气道炎症。评估支气管肺泡灌洗液中的总细胞和分类细胞计数以及细胞因子和趋化因子水平。检查肺组织中的细胞浸润和粘液过度分泌以及炎症生物标志物的表达。通过直接气道阻力分析监测气道高反应性。青蒿琥酯呈剂量依赖性抑制 OVA 诱导的总细胞和嗜酸性粒细胞计数、IL-4、IL-5、IL-13 和 eotaxin 水平升高。它减弱了 OVA 诱导的肺组织嗜酸性粒细胞浸润和气道粘液产生、肺组织中 E-选择素、IL-17、IL-33 和 Muc5ac 的 mRNA 表达以及对乙酰甲胆碱的气道高反应性。在正常的人支气管上皮细胞中,青蒿琥酯阻断表皮生长因子诱导的 Akt 及其下游底物 tuberin、p70S6 激酶和 4E 结合蛋白 1 的磷酸化以及 NF-κB 的转位激活。同样,青蒿琥酯阻断了 OVA 激发的小鼠肺组织中 Akt 及其下游底物的磷酸化。在屋尘螨诱导的小鼠哮喘模型中进一步证实了青蒿琥酯的抗炎作用。
结论/意义:青蒿琥酯通过负调控 PI3K/Akt 通路及其下游的 NF-κB 活性来改善实验性过敏性气道炎症。这些发现为青蒿琥酯治疗过敏性哮喘提供了新的治疗价值。